JCO at ASCO 2026: Individualized Neoantigen Therapy Plus Pembrolizumab in Melanoma

from Journal of Clinical Oncology (JCO) Podcast · host bumper-verify-6ac4346b

JCO Editorial Fellow Dr. Ash Gurumurthi and JCO Associate Editor Dr. Grant McArthur discuss the ASCO 2026 Simultaneous Publication paper "Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase 2b KEYNOTE-942 Study." LINK TO FULL TRANSCRIPT

Episode metadata supplied by the publisher feed · Published Jun 1, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

JCO at ASCO 2026: Individualized Neoantigen Therapy Plus Pembrolizumab in Melanoma

0:00 10:28

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Journal of Clinical Oncology (JCO) Podcast?

This episode is 10 minutes long.

When was this Journal of Clinical Oncology (JCO) Podcast episode published?

This episode was published on June 1, 2026.

Can I download this Journal of Clinical Oncology (JCO) Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!